posted on 2020-08-07, 15:34authored byRachel L. Palte, Sebastian E. Schneider, Michael D. Altman, Robert P. Hayes, Shuhei Kawamura, Brian M. Lacey, My Sam Mansueto, Michael Reutershan, Phieng Siliphaivanh, Christopher Sondey, Haiyan Xu, Zangwei Xu, Yingchun Ye, Michelle R. Machacek
Protein
arginine methyltransferase 5 (PRMT5) belongs to a family
of enzymes that regulate the posttranslational modification of histones
and other proteins via methylation of arginine. Methylation of histones
is linked to an increase in transcription and regulates a manifold
of functions such as signal transduction and transcriptional regulation.
PRMT5 has been shown to be upregulated in the tumor environment of
several cancer types, and the inhibition of PRMT5 activity was identified
as a potential way to reduce tumor growth. Previously, four different
modes of PRMT5 inhibition were knowncompeting (covalently
or non-covalently) with the essential cofactor S-adenosyl methionine
(SAM), blocking the substrate binding pocket, or blocking both simultaneously.
Herein we describe an unprecedented conformation of PRMT5 in which
the formation of an allosteric binding pocket abrogates the enzyme’s
canonical binding site and present the discovery of potent small molecule
allosteric PRMT5 inhibitors.